Nature Communications (Feb 2022)

Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis

  • Yiwu Yan,
  • Bo Zhou,
  • Chen Qian,
  • Alex Vasquez,
  • Mohini Kamra,
  • Avradip Chatterjee,
  • Yeon-Joo Lee,
  • Xiaopu Yuan,
  • Leigh Ellis,
  • Dolores Di Vizio,
  • Edwin M. Posadas,
  • Natasha Kyprianou,
  • Beatrice S. Knudsen,
  • Kavita Shah,
  • Ramachandran Murali,
  • Arkadiusz Gertych,
  • Sungyong You,
  • Michael R. Freeman,
  • Wei Yang

DOI
https://doi.org/10.1038/s41467-022-28340-6
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 17

Abstract

Read online

Distant metastasis is a major reason for mortality in patients with prostate cancer (PC). Here, the authors show that receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and its targeting impairs PC metastasis development.